Table 1.
Method | Technique | Role | Advantages | Disadvantages | Ref |
---|---|---|---|---|---|
CT | HRCT |
• Lung anatomy/morphology assessment • Disease progression evaluation • Treatment response evaluation |
+ quick + easy to apply + well established in clinical practice + high spatial resolution |
- ionizing radiation method - lack of pulmonary function assessment |
[16–19] |
CT | CV-HRCT |
• Lung anatomy/morphology assessment in infants • Disease progression evaluation • Treatment response evaluation |
+ assess lung changes in infants + high spatial resolution |
- ionizing radiation method - lack of pulmonary function assessment |
[20–24] |
MRI | IV CE-MRI |
• Assessment of pulmonary vascular bed perfusion • Lung structure evaluation |
+ Radiation free method + pulmonary function assessment (perfusion) |
- not applicable for all patients (metal parts in body, pacemaker etc.) - low spatial resolution due to low proton density of lungs - GD contrast can cause allergies |
[27, 29–31] |
MRI | 3He MRI |
• Assessment of ventilation and diffusion functional imaging • Disease progression evaluation • Treatment response evaluation |
+ radiation free method + sensitive track early progression of the disease, early treatment response + quantitative information about function (ventilation defect, apparent diffusion coefficient) |
- not applicable for all patients (metal parts in body, pacemaker etc.) - low spatial resolution due to low proton density of lungs - currently not applicable to infants due to complicated protocol |
[34–44] |
MRI | 129Xe MRI |
• Assessment of ventilation, diffusion and perfusion possible during one imaging protocol • Disease progression evaluation • Treatment response evaluation |
+ radiation free method + sensitive- track early progression of the disease, early treatment response + in-vivo observation of gas dissolution into barrier and RBCs + quantitative information about function (ventilation defect, apparent diffusion coefficient, gas-transfer defect) |
- not applicable for all patients (metal parts in body, pacemaker etc.) - low spatial resolution due to low proton density of lungs - up to date not applicable to infants due to complicated protocol - potentially hazardous due to Xe anaesthetic properties |
[46–50, 52] |
MRI | Non CE-MRI: ASL |
• Assessment of perfusion • Disease progression evaluation |
+ radiation free method + pulmonary function assessment (perfusion) + quantitative information (perfusion heterogeneity) |
- not applicable for all patients (metal parts in body, pacemaker etc.) - low spatial resolution due to low proton density of lungs |
[55, 58] |
MRI | Non CE-MRI: FD MRI |
• Assessment of ventilation and perfusion • Disease progression evaluation |
+ radiation free method + pulmonary function assessment (perfusion and ventilation) + quantitative information (perfusion homogeneity + results comparable to single photon emission CT and CE-MRI but without exogenous contrast |
- not applicable for all patients (metal parts in body, pacemaker etc.) - low spatial resolution due to low proton density of lungs |
[60, 61] |
MRI | Non CE-MRI: nT1 |
• Assessment of perfusion • Disease progression evaluation |
+ radiation free method + pulmonary function assessment (perfusion and ventilation) + quantitative information (dissolution phase homogeneity) |
- not applicable for all patients (metal parts in body, pacemaker etc.) - low spatial resolution due to low proton density of lungs |
[62, 63] |
MRI | Non CE-MRI: DWI | • Assessment of diffusion changes to localize mucus plugs |
+ radiation free method + diffusion changes- localization of areas with elevated diffusion called hotspots |
- not applicable for all patients (metal parts in body, pacemaker etc.) - low spatial resolution due to low proton density of lungs |
[65] |
Synchrotron based X-Ray | Phase contrast x-ray imaging | • Assessment of structural and functional changes in a microscale |
+ very high spatial and temporal resolution of images + cimaging function and morphology in microscale |
- ionizing radiation method- not applicable for humans | [66, 68–70] |